Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes

Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Calcium (Ca2+) mishandling is one of the most striking abnormalities in this wide spectrum of pathologies, among which heart failure (HF) remains the leading cause of death in developed countries (Benjamin et al., 2018...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mundiña-Weilenmann, Cecilia, Mattiazzi, Alicia Ramona
Formato: Articulo Comunicacion
Lenguaje:Inglés
Publicado: 2019
Materias:
Ciencias Médicas
Heart failure
Nitroxyl
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/107845
http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6571997&blobtype=pdf
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-107845
record_format dspace
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
Heart failure
Nitroxyl
spellingShingle Ciencias Médicas
Heart failure
Nitroxyl
Mundiña-Weilenmann, Cecilia
Mattiazzi, Alicia Ramona
Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
topic_facet Ciencias Médicas
Heart failure
Nitroxyl
description Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Calcium (Ca2+) mishandling is one of the most striking abnormalities in this wide spectrum of pathologies, among which heart failure (HF) remains the leading cause of death in developed countries (Benjamin et al., 2018). A hallmark of HF in both human and animal models is impaired Ca2+ sequestration into the SR, which contributes to the decreased contractile performance in this disease (Gwathmey et al., 1987; Meyer et al., 1995; del Monte et al., 2002). Not surprisingly, this defective mechanism has been targeted with novel therapeutic strategies that are now undergoing experimental and clinical testing in animals and patients (Pfeffer et al., 2015; Hulot et al., 2016, 2017; Motloch et al., 2018). In this issue of JGP, Keceli et al. provide novel insights into the molecular mechanism from which nitroxyl (HNO), nitric oxide (NO)’s one-electron-reduced and protonated sibling, recently emerged as a promising candidate for HF treatment.
format Articulo
Comunicacion
author Mundiña-Weilenmann, Cecilia
Mattiazzi, Alicia Ramona
author_facet Mundiña-Weilenmann, Cecilia
Mattiazzi, Alicia Ramona
author_sort Mundiña-Weilenmann, Cecilia
title Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
title_short Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
title_full Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
title_fullStr Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
title_full_unstemmed Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
title_sort tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
publishDate 2019
url http://sedici.unlp.edu.ar/handle/10915/107845
http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6571997&blobtype=pdf
work_keys_str_mv AT mundinaweilenmanncecilia trackingnitroxylderivedposttranslationalmodificationsofphospholambanincardiacmyocytes
AT mattiazzialiciaramona trackingnitroxylderivedposttranslationalmodificationsofphospholambanincardiacmyocytes
bdutipo_str Repositorios
_version_ 1764820443694366720

Ejemplares similares